OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Denduluri on Treatment Approaches in Early-Stage HR+/HER2- Breast Cancer

April 7th 2020

Neelima Denduluri, MD, shares treatment approaches in patients with early-stage hormone receptor-positive, HER2-negative breast cancer.

Dr. Wang on Ongoing Research in MCL

April 7th 2020

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses ongoing research in mantle cell lymphoma (MCL).

Dr. Barr on Umbralisib/Ublituximab/Venetoclax in Relapsed/Refractory CLL

April 7th 2020

Paul M. Barr, MD, Wilmot Cancer Institute, University of Rochester, discusses the results of a phase I/II study evaluating the combination of umbralisib, ublituximab, and venetoclax (Venclexta) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

Dr. Coffman on Safety Concerns With PARP Inhibitors in Ovarian Cancer

April 7th 2020

Lan G. Coffman, MD, PhD, assistant professor at the University of Pittsburgh Medical (UPMC) Center Hillman Cancer Center, discusses safety concerns with PARP inhibitors in ovarian cancer.

Dr. Boisen on Selecting Patients for Surgery Versus Neoadjuvant Chemotherapy in Ovarian Cancer

April 7th 2020

Michelle M. Boisen, MD, discusses criteria for selecting patients with ovarian cancer for upfront surgery versus neoadjuvant chemotherapy.

Dr. Penson on Re-Challenging With PARP Inhibition in Ovarian Cancer

April 4th 2020

Richard T. Penson, MD, MRCP, associate professor of medicine, Harvard Medical School, and clinical director of Medical Gynecologic Oncology, in the Department of Medicine, Massachusetts General Hospital, discusses re-challenging with PARP inhibition in patients with ovarian cancer.

Dr. Crew on Updated Data With Margetuximab in HER2+ Breast Cancer

April 4th 2020

Katherine D. Crew, MD, MS, director of Clinical Breast Cancer Prevention Program, Columbia University Irving Medical Center, and director of DataBase Shared Resource at Herbert Irving Comprehensive Cancer Center, Columbia University, discusses updated data with margetuximab in HER2-positive breast cancer.

Dr. Goodman on the Importance of the ECHELON-2 Data in PTCL

April 4th 2020

Aaron Goodman, MD, hematologist/oncologist and assistant professor of medicine at the University of California, San Diego, discusses the importance of the phase III ECHELON-2 data in peripheral T-cell lymphoma (PTCL).

Dr. Mok Previews Discussion Topics for the Upcoming COVID-19 Webinar

April 4th 2020

Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, previews discussion topics for the upcoming webinar hosted by OncLive on the novel coronavirus 2019 (COVID-19).

Dr. Levy on Emerging Biomarkers and Corresponding Therapies in Lung Cancer

April 4th 2020

Benjamin P. Levy, MD, discusses emerging biomarkers and their respective therapies in lung cancer.

Dr. Friedman on the Mechanism of Action of Selinexor in Multiple Myeloma

April 4th 2020

Robb S. Friedman, MD, discusses the mechanism of action of selinexor in multiple myeloma.

Dr. Fendler on Rationale for Creating the 68Ga-PSMA-11 PET in Prostate Cancer

April 4th 2020

Wolfgang Fendler, MD, discusses the rationale for creating the 68Ga-PSMA-11 PET in prostate cancer.

Dr. Armaghany on Frontline Sorafenib Versus Lenvatinib in Unresectable HCC

April 4th 2020

Tannaz Armaghany, MD, discusses sorafenib versus lenvatinib as first-line therapy for patients with hepatocellular carcinoma.

Dr. Simeone on Selecting Patients With Pancreatic Cancer for Neoadjuvant Therapy

April 4th 2020

Diane M. Simeone, MD, explains which patients with pancreatic cancer should receive neoadjuvant therapy.

Dr. Raphael on Addressing the Risk of Tumor Lysis Syndrome in CLL

April 4th 2020

Bruce G. Raphael, MD, discusses the risk of tumor lysis syndrome in chronic lymphocytic leukemia.

Dr. Choi on the Utility of Duvelisib in CLL

April 4th 2020

Michael Choi, MD, discusses the utility of duvelisib in chronic lymphocytic leukemia.

Dr. Pant on Choosing Therapy for Frontline and Beyond in Pancreatic Cancer

April 3rd 2020

Shubham Pant, MD, discusses choosing therapy for the frontline and beyond in pancreatic cancer.

Dr. Olawaiye on the Role of Surgery in Newly Diagnosed Ovarian Cancer

April 3rd 2020

Alexander B. Olawaiye, MD, discusses the role of surgery in women with newly diagnosed ovarian cancer.

Dr. Gomella on Potential Impact of Targeted Therapy Approvals on Genetic Testing in Prostate Cancer

April 3rd 2020

Leonard G. Gomella, MD, professor, chair of the Department of Urology, and director of the Sidney Kimmel Cancer Center Network, of Thomas Jefferson University Hospital, discusses the potential impact of targeted therapy approvals on the use of genetic testing in prostate cancer.

Dr. Hamid on the Evolution of Precision Medicine in Prostate Cancer

April 3rd 2020

Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the evolution of precision medicine in prostate cancer.